Adaptive Biotechnologies competitors

Experienced Chief Executive Officer with a demonstrated history of working in the biotechnology industry. Skilled in Life Sciences Research & Development (R&D), Strategy, Financing, Business Development & Entrepreneurship.

Yuval Cohen is a Co-Founder at Akari Therapeutics PLC; Chief Executive Officer at CORBUS PHARMACEUTICALS HOLDINGS, INC.; and Board Member at CORBUS PHARMACEUTICALS HOLDINGS, INC. and is based in Cambridge, Massachusetts. He has worked as SVP at CELSUS, President at Morria Biopharmaceuticals Plc, and President/CEO/Founder at Akari Therapeutics PLC. Yuval attended Univ Paris V Rene Descartes, Paris Las Vegas, and Cape Peninsula University of Technology between 2002 and 2002.

Experienced Public company Biotech CEO, with extensive fund raising experience that provides strategic advisory services to clients operating in biotech and medical technology. Over the past several years, I have developed strategic plans for both public companies as well as private companies. My extensive drug development experience has helped companies transition from pre-clinical to clinical stage. My experience running both private and public biotechnology companies has enhance my experiences in strategic and general corporate development topics related to venture funding, equity & debt financing along with M&A and capital market transactions.

As President and Chief Executive Officer of Seres Therapeutics, I’m focused on leading Seres with the belief that microbiome therapies can transform how disease is treated for individuals managing and living with serious disease. Through the combination of proprietary science, innovative technology and rigorous analysis, we’re striving to create a future that includes a revolutionary way of providing new treatment options to healthcare providers so patients can thrive from the inside out.My more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development and capital markets, drives me to help ensure Seres’ continued growth within the microbiome industry. Our steadfast commitment-from scientific discovery to fulfilling the promise of recovery-aims to help people live more fulfilling lives.

Patrick Soon-Shiong (born July 29, 1952) is a South African-American transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.

Elisabet De Los Pinos is a Board Member at Aura Biosciences and Founder & CEO at Aura Biosciences and is based in Cambridge, Massachusetts. She has worked as Brand Manager Oncology Business Unit at ELI LILLY & CO. Elisabet works or has worked as Post-Doctoral Fellow at Institute of Cancer Research/The. She studied at Institute of Cancer Research/The between 2000 and 2002, University of London between 2000 and 2002, and Icahn School of Medicine at Mount Sinai between 1999 and 1999.

Raymond Tesi is a Chair/Pres/CEO/Acting Chief Medical Ofcr at INmune Bio Inc., Chairman at INmune Bio Inc., and Board Member at Savant HWP. He has worked as CEO/President/Founder at Coronado Biosciences, Senior VP at SANGSTAT MEDICAL CORP, and Associate Professor at Tulane University School of Medicine. Raymond works or has worked as FELLOW at American College of Surgery. He attended Washington University in St LO and WASHINGTON UNIVERSITY.

Daniel 'Dan' Orlando is a Board Member at Alcresta Therapeutics and CEO at Alcresta Therapeutics and is based in Cambridge, Massachusetts. He has worked as Chief Business Officer at VERICEL CORP; Chief Commercial Officer at VERICEL CORP; and Vice President, Business Development at Takeda. Daniel studied at University of Florida between 1986 and 1987 and Florida Atlantic University between 1990 and 1991.